ϟ
DOI: 10.1093/annonc/mdh097
¤ OpenAccess: Hybrid
This work has “Hybrid” OA status. This means it is free under an open license in a toll-access journal.
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
Mary O’Brien,N. Wigler,Moshe Inbar,Riccardo Rosso,Eva‐Maria Grischke,Armando Santoro,Raphael Catane,D. G. Kieback,Piotr Tomczak,Stephen P. Ackland,F. Orlandi,L. Mellars,Leila Alland,Craig Tendler
Medicine
Cardiotoxicity
Doxorubicin
2004
Loading...
- MLA
- APA
- Chicago
- IEEE
- Harvard
- BibTeX
Cite this:
Generate Citation
“Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer” is a paper by Mary O’Brien N. Wigler Moshe Inbar Riccardo Rosso Eva‐Maria Grischke Armando Santoro Raphael Catane D. G. Kieback Piotr Tomczak Stephen P. Ackland F. Orlandi L. Mellars Leila Alland Craig Tendler published in 2004. It has an Open Access status of “hybrid”. You can read and download a PDF Full Text of this paper here.